Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2022 Aug 1;17(8):e0272380.
doi: 10.1371/journal.pone.0272380. eCollection 2022.

Chemical evidence for the tradeoff-in-the-nephron hypothesis to explain secondary hyperparathyroidism

Affiliations

Chemical evidence for the tradeoff-in-the-nephron hypothesis to explain secondary hyperparathyroidism

Kenneth R Phelps et al. PLoS One. .

Abstract

Background: Secondary hyperparathyroidism (SHPT) complicates advanced chronic kidney disease (CKD) and causes skeletal and other morbidity. In animal models of CKD, SHPT was prevented and reversed by reduction of dietary phosphate in proportion to GFR, but the phenomena underlying these observations are not understood. The tradeoff-in-the-nephron hypothesis states that as GFR falls, the phosphate concentration in the distal convoluted tubule ([P]DCT]) rises, reduces the ionized calcium concentration in that segment ([Ca++]DCT), and thereby induces increased secretion of parathyroid hormone (PTH) to maintain normal calcium reabsorption. In patients with CKD, we previously documented correlations between [PTH] and phosphate excreted per volume of filtrate (EP/Ccr), a surrogate for [P]DCT. In the present investigation, we estimated [P]DCT from physiologic considerations and measurements of phosphaturia, and sought evidence for a specific chemical phenomenon by which increased [P]DCT could lower [Ca++]DCT and raise [PTH].

Methods and findings: We studied 28 patients ("CKD") with eGFR of 14-49 mL/min/1.73m2 (mean 29.9 ± 9.5) and 27 controls ("CTRL") with eGFR > 60 mL/min/1.73m2 (mean 86.2 ± 10.2). In each subject, total [Ca]DCT and [P]DCT were deduced from relevant laboratory data. The Joint Expert Speciation System (JESS) was used to calculate [Ca++]DCT and concentrations of related chemical species under the assumption that a solid phase of amorphous calcium phosphate (Ca3(PO4)2 (am., s.)) could precipitate. Regressions of [PTH] on eGFR, [P]DCT, and [Ca++]DCT were then examined. At filtrate pH of 6.8 and 7.0, [P]DCT was found to be the sole determinant of [Ca++]DCT, and precipitation of Ca3(PO4)2 (am., s.) appeared to mediate this result. At pH 6.6, total [Ca]DCT was the principal determinant of [Ca++]DCT, [P]DCT was a minor determinant, and precipitation of Ca3(PO4)2 (am., s.) was predicted in no CKD and five CTRL. In CKD, at all three pH values, [PTH] varied directly with [P]DCT and inversely with [Ca++]DCT, and a reduced [Ca++]DCT was identified at which [PTH] rose unequivocally. Relationships of [PTH] to [Ca++]DCT and to eGFR resembled each other closely.

Conclusions: As [P]DCT increases, chemical speciation calculations predict reduction of [Ca++]DCT through precipitation of Ca3(PO4)2 (am., s.). [PTH] appears to rise unequivocally if [Ca++]DCT falls sufficiently. These results support the tradeoff-in-the-nephron hypothesis, and they explain why proportional phosphate restriction prevented and reversed SHPT in experimental CKD. Whether equally stringent treatment can be as efficacious in humans warrants investigation.

PubMed Disclaimer

Conflict of interest statement

The authors have declared that no competing interests exist.

Figures

Fig 1
Fig 1. Linear regressions unaffected by pH or precipitation of Ca3(PO4)2 (am., s.).
Fig 2
Fig 2. Dependence of logSICa3(PO4)2 (am., s.) on pH in the DCT.
Fig 3
Fig 3. Regressions assuming pH 6.8 and precipitation of Ca3(PO4)2 (am., s.).
Fig 4
Fig 4. Regressions assuming pH 7.0 and precipitation of Ca3(PO4)2 (am., s.).
Fig 5
Fig 5. Regressions of [PTH] on eGFR and [Ca++]DCT after log-transformation of variables and standardization of logarithmic values.

Similar articles

References

    1. Levin A, Bakris GL, Molitch M, Smulders M, Tian J, Williams LA, et al.. Prevalence of abnormal serum vitamin D, PTH, calcium and phosphorus in patients with chronic kidney disease: results of the study to evaluate early kidney disease. Kidney Int. 2007; 71: 31–38. doi: 10.1038/sj.ki.5002009 - DOI - PubMed
    1. Malluche HH, Ritz E, Lange HP, Kutschera J, Hodgson M, Seiffert U, et al.. Bone histology in incipient and advanced renal failure. Kidney Int. 1976;9: 355–362. doi: 10.1038/ki.1976.42 - DOI - PubMed
    1. Kim SM, Long J, Montez-Rath M, Leonard M, Chertow GM. Hip fracture in patients with non-dialysis-requiring chronic kidney disease. J Bone Miner Res. 2016;31: 1803–1809. doi: 10.1002/jbmr.2862 - DOI - PubMed
    1. Ritz E, Stefanski A, Rambausek M. The role of the parathyroid glands in the uremic syndrome. Am J Kidney Dis. 1995;26: 808–813. doi: 10.1016/0272-6386(95)90448-4 - DOI - PubMed
    1. Lavi-Moshayoff V, Wasserman G, Meir T, Silver J, Naveh-Many T. PTH increases FGF23 gene expression and mediates the high FGF23 levels of experimental kidney failure: a bone parathyroid hormone feedback loop. Am J Physiol Renal Physiol. 2010;299: F882–F889. doi: 10.1152/ajprenal.00360.2010 - DOI - PubMed